Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report
- Tao Wu
- Jinmao Zhou
- Cunbang Wang
- Binbin Wang
- Shuting Zhang
- Hai Bai
Published online on: October 9, 2017
Copyright: © Wu et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
Multiple myeloma (MM) is a common B‑cell hematological malignancy in the clinic. Bortezomib is the first‑in‑class proteasome inhibitor that has been approved for the treatment of patients with MM in the bone marrow. The present study report the case of an 83‑year‑old man who showed marked weakness, fatigue and a poor appetite. The patient was admitted to the Department of Nephrology due to severe renal impairment (RI). Immunofixation electrophoresis indicated a λ light chain‑positive status. There were 19.2% plasmablasts and proplasmacytes in the bone marrow. Positivity for the cell surface markers cluster of differentiation (CD)13, CD33, CD38 and human leukocyte antigen‑antigen D‑related was detected by flow cytometry. The patient was diagnosed with MM, λ light chain type, stage IIIB, and received bortezomib and dexamethasone regimen chemotherapy. RI was improved following the chemotherapy, and plasmablasts and proplasmacytes were almost eliminated. The Hb level was maintained at ~90 g/l. Overall, the present case report suggests that bortezomib may be safe and effective for elderly patients, even those >80 years of age, with severe RI.